S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
The Incredible Dividend Map... Where Stocks Yield 26% a Year! (Ad)pixel
'The Sacrifice Zone': Myanmar bears cost of green energy
Ralph Lauren Is A Retail Stock You Can Buy And Hold
Closing prices for crude oil, gold and other commodities
The Incredible Dividend Map... Where Stocks Yield 26% a Year! (Ad)pixel
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
The Incredible Dividend Map... Where Stocks Yield 26% a Year! (Ad)pixel
'The Sacrifice Zone': Myanmar bears cost of green energy
Ralph Lauren Is A Retail Stock You Can Buy And Hold
Closing prices for crude oil, gold and other commodities
The Incredible Dividend Map... Where Stocks Yield 26% a Year! (Ad)pixel
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
The Incredible Dividend Map... Where Stocks Yield 26% a Year! (Ad)pixel
'The Sacrifice Zone': Myanmar bears cost of green energy
Ralph Lauren Is A Retail Stock You Can Buy And Hold
Closing prices for crude oil, gold and other commodities
The Incredible Dividend Map... Where Stocks Yield 26% a Year! (Ad)pixel
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
S&P 500   4,122.47
DOW   32,774.41
QQQ   317.08
Are Medtronic And Intuitive Surgical Poised For Big Growth?
The Incredible Dividend Map... Where Stocks Yield 26% a Year! (Ad)pixel
'The Sacrifice Zone': Myanmar bears cost of green energy
Ralph Lauren Is A Retail Stock You Can Buy And Hold
Closing prices for crude oil, gold and other commodities
The Incredible Dividend Map... Where Stocks Yield 26% a Year! (Ad)pixel
Learning from failures: How Biden scored win on climate plan
Most electric vehicles won't qualify for federal tax credit
Is Sofi Financial Stock Finally Ready to Pay Off for Investors?
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
NASDAQ:RVLP

RVL Pharmaceuticals - RVLP Stock Forecast, Price & News

$1.60
+0.01 (+0.63%)
(As of 08/9/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.59
$1.65
50-Day Range
$1.21
$1.60
52-Week Range
$0.98
$4.38
Volume
67,710 shs
Average Volume
149,771 shs
Market Capitalization
$133.68 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
RVLP stock logo

About RVL Pharmaceuticals (NASDAQ:RVLP) Stock

RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. The company is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022. RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.

RVL Pharmaceuticals Price Performance

RVL Pharmaceuticals stock traded up $0.01 during midday trading on Tuesday, reaching $1.60. 67,710 shares of the company were exchanged, compared to its average volume of 149,771. The company has a market capitalization of $133.68 million, a price-to-earnings ratio of -1.82 and a beta of 1.64. The firm's 50-day simple moving average is $1.38 and its 200-day simple moving average is $1.48. RVL Pharmaceuticals has a 1 year low of $0.98 and a 1 year high of $4.38. The company has a debt-to-equity ratio of 0.65, a quick ratio of 2.75 and a current ratio of 2.79.

RVL Pharmaceuticals (NASDAQ:RVLP - Get Rating) last posted its quarterly earnings data on Thursday, May 12th. The company reported ($0.13) EPS for the quarter, topping analysts' consensus estimates of ($0.25) by $0.12. The firm had revenue of $21.44 million during the quarter, compared to analysts' expectations of $7.20 million. RVL Pharmaceuticals had a negative return on equity of 100.83% and a negative net margin of 163.45%. On average, analysts anticipate that RVL Pharmaceuticals will post -0.68 EPS for the current year.

Receive RVLP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for RVL Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RVLP Stock News Headlines

RVL Pharmaceuticals (NASDAQ:RVLP) Trading Up 2.9%
RVL’s UPNEEQ Product Wins Innovation Award
RVL Pharmaceuticals plc Ordinary Shares (RVLP)
RVL Pharmaceuticals plc (RVLP)
See More Headlines
Receive RVLP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for RVL Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RVLP Company Calendar

Last Earnings
5/12/2022
Today
8/10/2022
Next Earnings (Confirmed)
8/11/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RVLP
Fax
N/A
Employees
156
Year Founded
N/A

Profitability

Net Income
$-64,920,000.00
Net Margins
-163.45%
Pretax Margin
-199.04%

Debt

Sales & Book Value

Annual Sales
$17.50 million
Book Value
$0.92 per share

Miscellaneous

Free Float
79,189,000
Market Cap
$133.68 million
Optionable
Optionable
Beta
1.64

Key Executives

  • Mr. Brian A. Markison (Age 63)
    Chairman, Pres, CEO & Principal Financial Officer
    Comp: $664.62k
  • Mr. James D. Schaub (Age 40)
    Exec. VP & COO
    Comp: $519.97k
  • Mr. Christopher A. Klein (Age 57)
    Gen. Counsel & Sec.
    Comp: $511.6k
  • Mr. Michael J. DePetris (Age 45)
    Principal Accounting Officer
  • Mr. Jarret Miller
    Exec. VP of HR
  • Dr. Tina Marie deVries (Age 61)
    Exec. VP of R&D













RVLP Stock - Frequently Asked Questions

Should I buy or sell RVL Pharmaceuticals stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for RVL Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RVLP shares.
View RVLP analyst ratings
or view top-rated stocks.

How has RVL Pharmaceuticals' stock price performed in 2022?

RVL Pharmaceuticals' stock was trading at $1.17 at the beginning of the year. Since then, RVLP stock has increased by 36.8% and is now trading at $1.60.
View the best growth stocks for 2022 here
.

When is RVL Pharmaceuticals' next earnings date?

RVL Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our RVLP earnings forecast
.

How can I listen to RVL Pharmaceuticals' earnings call?

RVL Pharmaceuticals will be holding an earnings conference call on Thursday, August 11th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were RVL Pharmaceuticals' earnings last quarter?

RVL Pharmaceuticals plc (NASDAQ:RVLP) released its quarterly earnings results on Thursday, May, 12th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.12. The business earned $21.44 million during the quarter, compared to analyst estimates of $7.20 million. RVL Pharmaceuticals had a negative net margin of 163.45% and a negative trailing twelve-month return on equity of 100.83%.

What is RVL Pharmaceuticals' stock symbol?

RVL Pharmaceuticals trades on the NASDAQ under the ticker symbol "RVLP."

Who are RVL Pharmaceuticals' major shareholders?

RVL Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Marietta Wealth Management LLC (0.14%).

How do I buy shares of RVL Pharmaceuticals?

Shares of RVLP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is RVL Pharmaceuticals' stock price today?

One share of RVLP stock can currently be purchased for approximately $1.60.

How much money does RVL Pharmaceuticals make?

RVL Pharmaceuticals (NASDAQ:RVLP) has a market capitalization of $133.68 million and generates $17.50 million in revenue each year. The company earns $-64,920,000.00 in net income (profit) each year or ($0.88) on an earnings per share basis.

How many employees does RVL Pharmaceuticals have?

RVL Pharmaceuticals employs 156 workers across the globe.

How can I contact RVL Pharmaceuticals?

RVL Pharmaceuticals' mailing address is 400 Crossing Blvd, Bridgewater, New Jersey 08807-2863. The official website for the company is www.osmotica.com. The company can be reached via phone at (908) 809-1300 or via email at lwilson@insitecony.com.

This page (NASDAQ:RVLP) was last updated on 8/10/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.